Business
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease (cLDD). The clinical study is being conducted at up to 15 sites in the United States. \"Announcing first patient enrollment is our most significant clinical milestone to date and an exciting milestone for BioRestorative’s clinical programs overall,” said Lance Alstodt, CEO of BioRestorative Therapies. “The initiation of patient enrollment in our study reinforces our commitment to treating back pain and is an important step in our efforts to provide patients with potentially improved therapeutic options to treat chronic lumbar disc disease. In addition, I am very proud of the BRTX team for its timely execution. This truly remarkable accomplishment of first patient enrolled in only 6 months from our trial initiation keeps us on schedule to meet our strategic targets.” BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company’s autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion. \"Even with the rapid advancements in regenerative medicine across many musculoskeletal disorders over the last decade, there still remain many patients who continue to face unmet needs and experience a high burden of pain and disability,\" said Jason Lipitz, M.D., primary investigator in the clinical trial. \"With BioRestorative’s trial now underway, we look forward to seeing the potential clinical impact of BRTX-100 to treat chronic lumbar disc disease, which could be a paradigm shift in treating back pain.\" About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, ...